{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:43:05Z","timestamp":1792896185467,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jbo.2025.100717","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:08Z","timestamp":1760141228000},"page":"100717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0042-3321","authenticated-orcid":false,"given":"Nokitaka","family":"Setsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jbo.2025.100717_b0005","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2025.100717_b0010","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100717_b0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100717_b0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"9165","key":"10.1016\/j.jbo.2025.100717_b0025","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jbo.2025.100717_b0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.jbo.2025.100717_b0035","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2025.100717_b0040","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2025.100717_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J. Bone Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100717_b0050","first-page":"1157","article-title":"Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents","volume":"23","author":"Patrick","year":"2015","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2025.100717_b0055","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.jbo.2025.100717_b0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOMtTrial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.jbo.2025.100717_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010152","article-title":"Denosumab Discontinuation and the Rebound Phenomenon: a Narrative Review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100717_b0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","article-title":"The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation","volume":"40","author":"Schini","year":"2025","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.jbo.2025.100717_b0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","article-title":"Osteoclast recycling and the rebound phenomenon following denosumab discontinuation","volume":"20","author":"Kim","year":"2022","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2025.100717_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100423","article-title":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach","volume":"34","author":"Jacobson","year":"2022","journal-title":"J. Bone Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2025.100717_b0085","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2025.100717_b0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jbo.2025.100717_b0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2018.12.012","article-title":"Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review","volume":"120","author":"Roux","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.jbo.2025.100717_b0100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-022-06369-z","article-title":"Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer","volume":"33","author":"Wang","year":"2022","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jbo.2025.100717_b0105","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep."},{"issue":"1","key":"10.1016\/j.jbo.2025.100717_b0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.11005\/jbm.24.803","article-title":"Incidence of Hypercalcemia and Vertebral Fractures following Denosumab Withdrawal in Lung Cancer patients: a Longitudinal Cohort Study","volume":"32","author":"Villanova","year":"2025","journal-title":"J. Bone Metab."},{"issue":"3","key":"10.1016\/j.jbo.2025.100717_b0115","first-page":"1629","article-title":"Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial","volume":"29","author":"Miyashita","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2025.100717_b0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-020-05712-4","article-title":"Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate","volume":"182","author":"Miyashita","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2025.100717_b0125","doi-asserted-by":"crossref","unstructured":"Y. Singh, S.K. Barua, S. Trivedi, R. Tp, M. Pratim Kashyap, L. Kumar Agrawal, U. Kumar Pathak, N. Garg, Skeletal-Related events in renal cell carcinoma: prediction with alkaline phosphatase (ALP), C-reactive Protein (CRP), Haemoglobin (Hb) and Erythrocyte Sedimentation Rate (ESR) (A.C.H.E.) Score for Risk Stratification, Cureus 15(6) (2023) e40835.","DOI":"10.7759\/cureus.40835"},{"issue":"28","key":"10.1016\/j.jbo.2025.100717_b0130","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042990","article-title":"Percentile-based reference values for serum alkaline phosphatase at birth in Japanese preterm and term infants: a retrospective cohort study","volume":"104","author":"Hara","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jbo.2025.100717_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197984","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy chinese volunteers: a randomized, single-blind, placebo-controlled study","volume":"13","author":"Chen","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jbo.2025.100717_b0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.jbo.2025.100717_b0145","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100717_b0150","doi-asserted-by":"crossref","unstructured":"Skeletal Complications of Malignancy. Proceedings of a symposium. Bethesda, Maryland, April 19-20, 1997, Cancer 80(8 Suppl) (1997) 1527-701.","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1527::AID-CNCR1>3.0.CO;2-H"},{"issue":"1","key":"10.1016\/j.jbo.2025.100717_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100717_b0160","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","article-title":"Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications","volume":"41","author":"D'Oronzo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2025.100717_b0165","doi-asserted-by":"crossref","unstructured":"J.R. Gralow, J.S. Biermann, A. Farooki, M.N. Fornier, R.F. Gagel, R. Kumar, G. Litsas, R. McKay, D.A. Podoloff, S. Srinivas, C.H. Van Poznak, NCCN task force report: bone health in cancer care, J. Natl. Compr. Canc. Netw. 11 Suppl 3 (2013) S1-50; quiz S51.","DOI":"10.6004\/jnccn.2013.0215"},{"key":"10.1016\/j.jbo.2025.100717_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100694","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOFCABS, ECTS, IEG, ESCEO, IMS, and SIOG","volume":"53","author":"Hadji","year":"2025","journal-title":"J Bone Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2025.100717_b0175","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2025.100717_b0180","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.jbo.2025.100717_b0185","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/10600280231168456","article-title":"Prevention of skeletal-related events with extended-interval denosumab: a review of the literature","volume":"58","author":"Keisner","year":"2024","journal-title":"Ann. Pharmacother."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:26:51Z","timestamp":1765024011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137425000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S2212137425000582"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100717","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100717"}}